Updated Daily

Latest News

Daily updates on peptide research, clinical trials, regulatory changes, and site additions.

Site UpdateMay 21, 2026

6 New Peptides Added: MK-677, LL-37, KPV, SS-31, Humanin & Dihexa

PeptideWiki has expanded its database with six highly-requested research peptides. The additions span growth hormone secretagogues (MK-677/Ibutamoren), innate immunity (LL-37/Cathelicidin), gut anti-inflammatories (KPV), mitochondrial medicine (SS-31/Elamipretide, Humanin), and cognitive enhancement (Dihexa). Each entry includes full mechanism breakdowns, dosage protocols, research applications, and key citations.

MK-677LL-37KPVSS-31HumaninDihexasite updatenew peptides

Site UpdateMay 21, 2026

MK-677 (Ibutamoren) Added — The Only Orally Bioavailable GH Secretagogue

MK-677 is now on PeptideWiki. As the only oral GH secretagogue with Phase 2/3 human trial data, it offers a distinct profile from injectable GH peptides: 24-hour half-life, 40–90% IGF-1 elevation, documented lean mass gains in elderly adults, and improved slow-wave sleep. Entry covers GHSR-1a mechanism, sleep architecture effects, sarcopenia trial data, and adverse effect monitoring.

MK-677Ibutamorengrowth hormoneIGF-1oralGHS

View peptide

Site UpdateMay 21, 2026

LL-37 (Cathelicidin) Added — The Only Human Antimicrobial Peptide

LL-37 is now on PeptideWiki. The sole human cathelicidin, LL-37 is a multifunctional 37-amino acid peptide that kills bacteria via membrane disruption, disrupts biofilms, modulates innate immune responses, and accelerates wound healing via EGFR transactivation. Its deficiency underlies atopic dermatitis, chronic rhinosinusitis, and recurrent infections. Entry covers antimicrobial spectrum, immunomodulation via FPRL1/FPR2, and wound healing mechanisms.

LL-37cathelicidinantimicrobialinnate immunitywound healing

View peptide

Site UpdateMay 21, 2026

KPV Added — α-MSH Tripeptide Fragment for Gut Inflammation

KPV (Lys-Pro-Val), the anti-inflammatory C-terminal tripeptide of α-MSH, is now on PeptideWiki. At 328 Da, its small size enables oral bioavailability and deep mucosal penetration — an advantage over full α-MSH for gastrointestinal applications. Nanoparticle-formulated KPV achieved colitis remission comparable to mesalamine in multiple preclinical IBD models. Entry covers NF-κB inhibition, epithelial barrier repair, and gut-targeted delivery systems.

KPValpha-MSHIBDgut healthanti-inflammatoryNF-κB

View peptide

Site UpdateMay 21, 2026

SS-31 (Elamipretide) Added — First Mitochondria-Targeted Peptide with Phase 3 Data

SS-31 (Elamipretide/MTP-131) is now on PeptideWiki. The SPARCLE Phase 3 trial demonstrated significant improvements in 6-minute walk test and quality of life in heart failure — making SS-31 the first mitochondria-targeted therapy to reach positive Phase 3 outcomes. Its mechanism centers on cardiolipin binding at the inner mitochondrial membrane, preserving cristae architecture and ATP synthase efficiency. Entry covers cardiolipin biology, SPARCLE/TAZPOWER trial data, and Barth syndrome application.

SS-31Elamipretidemitochondriaheart failureBarth syndromecardiolipin

View peptide

Site UpdateMay 21, 2026

Humanin Added — The Mitochondrial Longevity Signal Found in Centenarians

Humanin is now on PeptideWiki. The founding mitochondria-derived peptide (MDP), Humanin is encoded by the mitochondrial 16S rRNA region and signals systemically as a longevity factor. Centenarians maintain significantly higher circulating humanin levels than age-matched controls. It suppresses neuronal apoptosis (Bax inhibition), improves insulin sensitivity via gp130/WSX-1 receptors, and protects the heart from ischemia-reperfusion injury. Entry covers MDP biology, centenarian data, and HNG analogue pharmacology.

HumaninmitochondrialongevitycentenarianAlzheimer'sapoptosisMDP

View peptide

Site UpdateMay 21, 2026

Dihexa Added — Angiotensin IV Mimetic with Extraordinary Synaptogenic Potency

Dihexa is now on PeptideWiki. This synthetic angiotensin IV analogue (Washington State University) potentiates HGF/MET receptor signaling in the brain, inducing synaptogenesis and dendritic spine growth. Preclinical data reported ~10 million-fold greater potency vs. BDNF for synaptogenesis in hippocampal neurons. In aged cognitively-impaired rats, 5 days of treatment restored Morris Water Maze performance to young-animal levels. Blood-brain barrier penetrant via oral or transdermal routes.

DihexacognitivenootropicHGFMET receptorsynaptogenesisAlzheimer's

View peptide

Site UpdateApril 11, 2026

NAD+ Added to Longevity Category

NAD+ (Nicotinamide Adenine Dinucleotide) has been added to PeptideWiki's Longevity category. The entry covers sirtuin activation, PARP-mediated DNA repair, mitochondrial function, and the age-related ~50% NAD+ decline. Includes 5 key citations from Cell Metabolism, Science, and npj Aging.

NAD+longevitysirtuinsNMNNR

View peptide

researchDecember 1, 2025

New PMC Study Confirms Epithalon Telomere Elongation via Telomerase

A 2025 PMC publication (Kossoy et al.) provides independent Western validation of Epithalon's telomere-lengthening mechanism, confirming TERT upregulation in human cell lines. This represents important replication of the Khavinson group's 30+ year dataset outside of Russian research institutions.

EpithalontelomeretelomeraseTERTlongevity

View peptide Source

regulatoryJanuary 1, 2024

MOTS-c Added to WADA Prohibited List

MOTS-c was added to the World Anti-Doping Agency's prohibited substances list in 2024, classified as a prohibited peptide hormone. This reflects the sports science community's assessment of its performance-enhancing potential via AMPK activation and exercise mimicry — a significant milestone for the young (2015) research peptide.

MOTS-cWADAanti-dopingAMPKexercise mimetic

View peptide

clinicalApril 20, 2022

NMN Raises Blood NAD+ in Older Men in Dose-Dependent Manner — Human Trial

Igarashi et al. (2022, npj Aging) demonstrated that chronic NMN supplementation significantly elevates blood NAD+ concentrations in healthy older men in a dose-dependent fashion. This human data strengthens the rationale for NMN as an NAD+ precursor for age-related NAD+ decline.

NMNNAD+longevityhuman trialaging

View peptide Source

clinicalAugust 18, 2021

NMN Improves Muscle Insulin Sensitivity in Postmenopausal Women — Science

Yoshino et al. (2021, Science) showed NMN supplementation improved skeletal muscle insulin signalling and NAD+ metabolism in premenopausal women with prediabetes. Published in Science, this is one of the highest-impact human NAD+ trials to date and the first to show tissue-level metabolic benefits.

NMNNAD+insulin sensitivityhuman trialmuscle

View peptide Source